share_log

Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7

Benzinga ·  Nov 9, 2023 09:02

Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $8 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment